Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

NCT01327014 is registered in ClinicalTrials.gov with Beijing Peking University WBL Biotech Co., Ltd. as lead sponsor.

NCT NCT01327014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01327014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
Lead sponsor
Beijing Peking University WBL Biotech Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2012
Enrollment
116 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia